Get the Stockscreener App
4.51
5.85%
-0.28
After Hours:
4.51
Relay Therapeutics Inc stock is traded at $4.51, with a volume of 1.03M.
It is down -5.85% in the last 24 hours and down -1.31% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$4.79
Open:
$4.81
24h Volume:
1.03M
Relative Volume:
0.45
Market Cap:
$754.90M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-1.6107
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
-0.66%
1M Performance:
-1.31%
6M Performance:
-37.27%
1Y Performance:
-50.60%
1-Day Range:
$4.51
$4.85
1-Week Range:
$4.25
$4.86
52-Week Range:
$3.50
$11.16
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
399 BINNEY STREET, CAMBRIDGE
Compare RLAY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
4.51 | 754.90M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - SETE News
BlackRock, Inc. Expands Stake in Relay Therapeutics Inc with Sig - GuruFocus.com
Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily
SG Americas Securities LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Brokerages - ETF Daily News
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
How should investors view Relay Therapeutics Inc (RLAY)? - US Post News
Is Relay Therapeutics Inc (NASDAQ: RLAY) Stock Worth Investing In for High Returns? - Marketing Sentinel
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 17,250 Shares - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 20,791 Shares - MarketBeat
Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells 36,036 Shares of Stock - MarketBeat
Relay Therapeutics Insider Sold Shares Worth $268,339, According to a Recent SEC Filing - Marketscreener.com
Relay Therapeutics Inc (RLAY) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Relay Therapeutics CEO Sanjiv Patel sells $1.76 million in stock - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down on Insider Selling - Defense World
Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells $600,000.00 in Stock - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Down 6%Here's What Happened - MarketBeat
Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Insider Selling - MarketBeat
Relay Therapeutics CEO Sanjiv Patel sells $1.76 million in stock By Investing.com - Investing.com UK
Relay Therapeutics (NASDAQ:RLAY) Trading 6.8% HigherHere's Why - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat
Relay Therapeutics' SWOT analysis: stock poised for growth amid fierce competition - MSN
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8%Time to Sell? - MarketBeat
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate - Yahoo Finance
Relay Therapeutics’ (RLAY) Buy Rating Reiterated at HC Wainwright - Defense World
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Given "Buy" Rating at HC Wainwright - MarketBeat
Lilly Pays Up To $2.5bn For Scorpion, Will Put Big Pharma Muscle Behind PI3Kα Inhibitor - Citeline News & Insights
Relay Therapeutics Highlights Progress at Healthcare Conference - TipRanks
Barclays PLC Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Barclays PLC Purchases 136,541 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws - MSN
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Relay Therapeutics stock hits 52-week low at $4 By Investing.com - Investing.com South Africa
Relay Therapeutics (NASDAQ:RLAY) Hits New 12-Month LowShould You Sell? - MarketBeat
Relay Therapeutics stock hits 52-week low at $4 - Investing.com India
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws (LLY:NYSE) - Seeking Alpha
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):